Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for Diverticulosis

TORRANCE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease   treatment, is pleased to announce that it has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-glutamine (PGLG) oral powder for use in the treatment of diverticulosis.  This is the same active pharmaceutical ingredient found in Endari®, which is approved by the FDA and the Israeli Ministry of Health to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Click to view original post